J Neurol Surg B Skull Base 2021; 82(S 02): S65-S270
DOI: 10.1055/s-0041-1725495
Presentation Abstracts
Poster Abstracts

Absence of Contrast Enhancement in a Petroclival Meningioma: Case Report and Systematic Literature Review

Adedamola Adepoju
1   Albany Medical Center, Albany, New York, United States
,
Ananth Narayan
1   Albany Medical Center, Albany, New York, United States
,
Mahmoud Aldyab
1   Albany Medical Center, Albany, New York, United States
,
David Foyt
1   Albany Medical Center, Albany, New York, United States
,
Maria Peris-Celda
1   Albany Medical Center, Albany, New York, United States
› Author Affiliations
 

Background: Meningioma is one of the most common intracranial tumors with well-established radiologic features such as contrast enhancement, dural tail, and hyperostosis on computed tomography and magnetic resonance imaging. Meningiomas enhance avidly on contrast-weighted images based on the tumor vascularity or underlying histopathology except for areas of necrosis or cyst. Even in this context, faint or nonenhancing meningioma is exceedingly rare. We are presenting a rare case of a patient with a nonenhancing meningioma in the cranial base with neither radiological features of cystic changes nor necrosis. The implication of the enhancement on pathological features and clinical outcomes is not known. A systematic review was performed to analyze minimal or nonenhancing meningioma with regard to tumor location, histological type, and prognosis.

Case Description and Imaging: A 57-year-old male presented with progressive right hearing loss, disequilibrium, occasional difficulty swallowing, and facial numbness. Noncontrast CT of the head revealed a hypodense right cerebellopontine angle mass extending from the interpeduncular and ambient cisterns to the foramen magnum ([Fig. 1A and B]). Magnetic resonance imaging showed a 5.2 cm × 3.8 cm × 5.5 cm (anteroposterior × lateral × craniocaudal) T1-weighted hypointense and T2-weighted hyperintense mass ([Fig. 1C and D]). The three-dimension fast imaging employing steady-state acquisition (FIESTA) sequence revealed the tumor also extended into the right internal acoustic canal (IAC, [Fig. E]) and Meckel's cave. The mass displayed an intermediate diffusion signal when compared with adjacent CSF ([Fig. 1F]). Gadoterate meglumine contrast injection did not reveal an apparent enhancement. There was a faint enhancement around the tentorium but no significant enhancement within the tumor ([Fig. 1G]).

Operative Procedure and Histopathological Analysis: The patient underwent a posterior petrosal approach for tumor resection ([Fig. 2]). The tumor stained for vimentin, GFAP, and Cyclin D1, with low Ki-67 (<2%), and with an epithelioid reticulin pattern ([Fig. 3]). The pathological analysis demonstrated a microcystic meningioma WHO grade I.

Systematic Review: Seven articles, including case reports and case series, had 14 verifiable cases included in the systemic review1–7. The average age was 48.1 years, and the majority were female (71.4%). Convexity meningioma was the common location at 57.1%. Two cases involved the skull base, and one case involved the lumbosacral region. All cases included a faint or nonenhancing meningioma. Microcystic meningioma was the most common histological type at 85.7% (12/14). Clear cell and fibrous meningioma were other histological types of nonenhancing meningioma, respectively. Two patients had radiotherapy for adjuvant treatment.

Discussion: Meningioma presented in this case lacked the typical features associated with the tumor including contrast enhancement, hyperostosis, and dural tail. The absence of these signs rendered meningioma as an unlikely diagnosis. However, the histopathology analysis indicated microcystic meningioma. The literature review indicated that the majority of unenhanced meningioma had microcystic histopathology. However, only 10.2% of microcystic meningiomas are nonenhancing.

Conclusion: Meningioma should be considered as a rare differential diagnosis for a nonenhancing lesion at the cerebellopontine and petroclival regions.

Zoom Image
Fig. 1
Zoom Image
Fig. 2
Zoom Image
Fig. 3 (A) H&E stain (×4), (B) vimentin, (C) cyclin-D, (D) reticulin, (E) GFAP, (F) Ki-67. H&E, hematoxylin and eosin.


Publication History

Article published online:
12 February 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany